1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Michael Dill: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) Fecal microbiota transfer, Vancomycin Oral Capsule, Atezolizumab + Bevacizumab - Immunotherapy, HCC - Hepatocellular Carcinoma | Phase 2 | Recruiting | Michael Dill | 48 | 2025-07-16 | 2025-08-06 |
Bevacizumab (1) · Fecal Microbiota Transplantation (1) · Vancomycin (1) · atezolizumab (1)
Germany (1)